Study evaluates treatment with troriluzole in patients with hereditary spinocerebellar ataxias

Researchers have reported promising results from Phase IIb/III trials examining the long-term effects of BHV-4157-201, or troriluzole, on hereditary spinocerebellar ataxias (SCAs) – potentially fatal, rare neurodegenerative disorders affecting the cerebellum.